Skip to content

You are about to review presentations, reports, filings and/or other materials regarding Amarin Corporation plc (NASDAQ: AMRN) that contain time-sensitive information. The information contained therein is only current as of the date thereof and may not be a complete listing of all documents filed with the Securities Exchange Commission, made public or provided to Amarin shareholders.


Amarin expressly disclaims any obligation to review, update or correct these materials after the date thereof. Amarin may update, amend, supplement or otherwise alter the information contained in any such materials by subsequent presentations, reports, filings, or other means without notice.


Certain statements made on this web site or in materials accessed in or through the investor relations section of our web site are "forward-looking statements," which are subject to risks and uncertainties, and Amarin's actual results may differ (possibly materially) from those indicated in such statements. A further list and description of these risks, uncertainties and other risks associated with an investment in Amarin can be found in Amarin's filings with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and its most recent Quarterly Report on Form 10-Q.


This website is not an offer or a solicitation to buy or sell securities. Please be aware that decisions regarding investments are the responsibility of users. Although this website includes information regarding pharmaceuticals (including products under development), the information is not intended as any advertisement and/or medical advice.


This information is intended for communication with investors and should not be construed as marketing the use of any Amarin products or product candidates.


Information on this website may be revised without any prior notice.

Company Profile

Investor Alert
Amarin Receives FDA Approval of VASCEPA® (icosapent ethyl) to Reduce Cardiovascular Risk
See press release here
Updated Label information

Company Profile

Amarin Corporation plc is a rapidly growing, innovative pharmaceutical company focused on developing and commercializing therapeutics to cost-effectively improve cardiovascular health. Amarin’s lead product, VASCEPA® (icosapent ethyl) capsules, is available by prescription in the United States and an increasing number of other countries. For more information about VASCEPA® visit

VASCEPA® (icosapent ethyl), capsules, was originally approved in 2012 to reduce severely elevated levels of triglycerides (500 milligrams per deciliter or higher), along with diet and exercise, in adult patients. This drug’s approval was expanded in 2019 as an adjunct to maximally tolerated statin therapy to reduce the risk of cardiovascular events in certain adults with elevated triglyceride levels of 150 milligrams per deciliter or higher and other cardiovascular risk factors. This is the first and only FDA approved drug to reduce cardiovascular risk in patients with elevated triglyceride levels as an add-on to maximally tolerated statin therapy. Statins are drugs used to treat elevated cholesterol levels and reduce the risk of cardiovascular events. VASCEPA® is a prescription medicine used along with certain medicines (statins) to reduce the risk of heart attack, stroke and certain types of heart issues requiring hospitalization in adults with heart (cardiovascular) disease, or diabetes and two (2) or more additional risk factors for heart disease.

VASCEPA® (icosapent ethyl) capsules are a single-molecule prescription product consisting of the omega-3 acid commonly known as EPA in ethyl-ester form. VASCEPA® is not fish oil, but is derived from fish through a stringent and complex FDA-regulated manufacturing process designed to effectively eliminate impurities and isolate and protect the single molecule active ingredient from degradation. VASCEPA®, known in scientific literature as AMR101, has been designated a new chemical entity by the FDA. Amarin has been issued multiple patents internationally based on the unique clinical profile of VASCEPA®, including the drug’s ability to lower triglyceride levels in relevant patient populations without raising LDL-cholesterol levels. For more information about VASCEPA® visit For more information about Amarin visit

If you are reporting an adverse event or product complaint, please email or call the Amarin Call Center at 1 855 VASCEPA.

» See important safety information about VASCEPA®
» See full prescribing information for VASCEPA®

Amarin reported primary results of the successful REDUCE-IT trial concurrent with presentation of these results at the 2018 Scientific Sessions of the American Heart Association on November 10, 2018 in Chicago, Illinois. Results can be found in our press release. Additional references to such results are provided in a slide presentation of such results and in our results investor presentation.

Amarin reported additional results of the successful REDUCE-IT trial at the American College of Cardiology’s 68th Annual Scientific Session. The press release on the data is here. Additional references to these results are provided in this slide presentation.

Amarin is headquartered in Dublin, Ireland. In the U.S., the company's office is in Bedminster, New Jersey. Amarin is listed in the U.S. on NASDAQ (symbol: "AMRN").


Title Documents

Amarin Q1 2020 Results Conference Call

Investor Call Discussing ACC Science

Cowen and Company's 40th Annual Health Care Conference

March 2020 Investor Presentation

9th Annual SVB Leerink Global Healthcare Conference

Corporate Governance

The Board of Directors of Amarin Corporation plc (the "Company") sets high standards for the Company's employees, officers and directors. Implicit in this philosophy is the importance of sound corporate governance. It is the duty of the Board of Directors to serve as a prudent fiduciary for shareholders and to oversee the management of the Company's business. To fulfill its responsibilities and to discharge its duty, the Board of Directors follows the procedures and standards that are set forth in these guidelines. These guidelines are subject to modification from time to time as the Board of Directors deems appropriate in the best interests of the Company or as required by applicable laws and regulations.

Title Documents

Articles of Association

Memorandum and Articles of Association

Code of Business Conduct and Ethics

CA Declaration of Compliance 2019

ADR List for 2020

Financial Information

Here you will find a summary of Amarin Corporation plc's latest financial information.

Latest Earnings

Title Date Supporting Information
Fourth Quarter Financial Results Feb 25, 2020

AMCO Statutory Accounts

Title Date Documents

2018 AMCO Statutory Accounts

Amarin Corporation